Skip to content

Cannabis: all studies

Page 163 of 287: studies 1,621 to 1,630 of 2,864, newest first. Back to the cannabis overview

Research

Is Cannabis Use a Contributory Cause of Psychosis?

The Canadian Journal of Psychiatry August 1, 2006 Louisa Degenhardt, Wayne Hall

Objective: To assess whether cannabis use in adolescence and young adulthood is a contributory cause of schizophreniform psychosis in that it may precipitate psychosis in vulnerable individuals. Method: We reviewed longitudinal studies of adolescents and young adults that examined the relations between self-reported cannabis use and the risk of diagnosis with a psychosis or of reporting...

Cannabis and other variables affecting age at onset in a schizophrenia founder population

African Journal of Psychiatry July 17, 2006 Johannes Lodewikus Roos, H.W. Pretorius, Maria Karayiorgou et al. 11 citations

Objective: An ongoing collaborative study between the Human Neurogenetic Laboratory of Rockefeller University, New York and the Department of Psychiatry at the University of Pretoria, has been taking place since 1997, to map genes for schizophrenia. Aspects of cannabis use/abuse will be reported.Method: The Diagnostic Interview for Genetic Studies [DIGS] is used for all diagnosis. A narrative...

Interactions between THC and cannabidiol in mouse models of cannabinoid activity.

Psychopharmacology June 2006 Stephen A Varvel, J L Wiley, R Yang et al.

Interest persists in characterizing potential interactions between Delta(9)-tetrahydocannabinol (THC) and other marijuana constituents such as cannabidiol (CBD). Such interactions may have important implications for understanding the long-term health consequences of chronic marijuana use as well as for attempts to develop therapeutic uses for THC and other CB(1) agonists. We investigated...

History of cannabis as a medicine: a review.

Revista Brasileira de Psiquiatria June 1, 2006 A. Zuardi

Cannabis as a medicine was used before the Christian era in Asia, mainly in India. The introduction of cannabis in the Western medicine occurred in the midst of the 19th century, reaching the climax in the last decade of that century, with the availability and usage of cannabis extracts or tinctures. In the first decades of the 20th century, the Western medical use of cannabis significantly...

[Effects of oral cannabis and dronabinol on driving capacity].

Annales pharmaceutiques francaises May 2006 Christian Giroud, Marc Augsburger, Bernard Favrat et al.

Two retrospective epidemiologic studies have shown that cannabis is the main psychoactive substance detected in the blood of drivers suspected of driving under the influence of psychotropic drugs. An oral administration double-blind crossover study was carried out with eight healthy male subjects, aged 22 to 30 years, all occasional cannabis smokers. Three treatments and one placebo were...

[Neurobiology of cannabis--recent data enlightening driving disturbances].

Annales pharmaceutiques francaises May 2006 J Costentin

During the last decades a new landscape of cannabis has been designed on account of: the increase in its use the greater youth of its users; the increase in the content of its main active constituent tetrahydrocannabinol (THC) and a lot of new epidemiological and neurobiological data. THC displays an exceptional lipophilicity, allowing its cerebral storage, leading to long lasting effects, by...

Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation.

Brain May 2006 L Chang, R Yakupov, C Cloak et al.

Attention and memory deficits have been reported in heavy marijuana users, but these effects may be reversible after prolonged abstinence. It remains unclear whether the reversibility of these cognitive deficits indicates that chronic marijuana use does not alter cortical networks, or that such changes occur but the brain adapts to the drug-induced changes. Blood oxygenation-level dependent...

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

Brazilian Journal of Medical and Biological Research April 1, 2006 Antônio Waldo Zuardi, José A. Crippa, Jaime E. C. Hallak et al. 411 citations

A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic...

Effects of marijuana on temporal discriminations in humans.

Behavioural Pharmacology March 2006 Lori M Lieving, Scott D Lane, Don R Cherek et al.

Marijuana has been reported to alter the discrimination of time. The present study used a psychophysical approach to examine the effects of marijuana on temporal discrimination in humans. Research participants were required to push one of two buttons depending on the duration of a conditional stimulus (a blue square on a computer monitor). Correct choices ('C' button after a 2-s stimulus; 'A'...

The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers.

American heart journal March 2006 David A. Gorelick, Stephen J Heishman, Kenzie L Preston et al.

Animal studies suggest that cannabinoid CB1 receptors play a role in regulating blood pressure (BP). In human studies, activation of CB1 receptors by cannabis or its active ingredient, Delta9-tetrahydrocannabinol (THC), has modest and inconsistent effects on BP. We evaluated this phenomenon in 63 male cannabis smokers (mean [SD] age 27.7 +/- 5.4 years, 70% African American, 10.3 +/- 5.9 years...